Tresiba injekcinis švirkštas, 100 TV/ml,, 5 vnt

Tresiba contains insulin degludec, an ultra-long-acting basal insulin analogue with a half-life of approximately 25 hours and a duration of action exceeding 42 hours. This exceptionally long and flat action profile provides the most stable basal insulin coverage available, with very low rates of hypoglycaemia. The extended duration also allows flexible dosing timing, with a minimum of eight hours between doses.

How to Use Tresiba

Tresiba (insulin degludec) is injected subcutaneously once daily. While a consistent daily time is ideal for routine, Tresiba is flexible — doses can be given at varying times if needed, with a minimum gap of eight hours between any two doses. This flexibility is a practical advantage for shift workers and those with irregular schedules.

Inject into the abdomen, thigh, or upper arm, rotating sites within the same region at each injection to prevent lipodystrophy (fatty lumps under the skin). Never inject into skin that is bruised, thickened, or damaged.

Preparing the Injection

Use a new needle for every injection. Prime the pen before first use by dialling two units and pressing until insulin appears at the needle tip. Allow refrigerated pens to warm to room temperature before injecting to reduce discomfort. Store opened pens at room temperature (below 30°C) for up to eight weeks.

Dose is individualised. Available in 100 and 200 units/ml. When switching from other basal insulins, start with a unit-for-unit conversion and adjust based on blood glucose monitoring.

Common Side Effects

• Hypoglycaemia (low blood sugar) — the most common and most important risk. Symptoms include shakiness, sweating, confusion, palpitations, and hunger. Always carry fast-acting glucose (glucose tablets, fruit juice, or sugary sweets)
• Injection site reactions (redness, swelling, or itching at the site)
• Lipodystrophy (fatty lumps or dimples under the skin) with repeated injection into the same spot — rotate sites carefully
• Weight gain

Hypoglycaemia Risk

The risk of hypoglycaemia is generally lower with Tresiba than with insulin glargine, as demonstrated in clinical trials. However, hypoglycaemia remains the main risk with all insulin therapy. Never drive or operate heavy machinery if you feel your blood sugar may be low. If hypoglycaemia is frequent, discuss your dose or meal timing with your diabetes team.

The 200 units/ml concentration delivers doses in units, not volume: do not transfer between different concentration pens. The FlexTouch pen has a dose counter.

Contraindicated in hypoglycaemia and known hypersensitivity to insulin degludec.